H.R.2178 - Cerebral Palsy Research Program Authorization Act of 2025 (119th Congress)
Summary
H.R.2178, the "Cerebral Palsy Research Program Authorization Act of 2025," aims to amend the Public Health Service Act. It authorizes the Secretary of Health and Human Services to establish a research program focused on cerebral palsy. The bill allocates $5 million annually from 2026 through 2031 for this research.
Expected Effects
The bill's passage would lead to increased federal funding for cerebral palsy research. This could result in advancements in diagnosis, treatment, and understanding of the condition. It may also improve the quality of life for individuals affected by cerebral palsy and their families.
Potential Benefits
- Increased research funding for cerebral palsy.
- Potential advancements in diagnosis and treatment.
- Improved understanding of the causes and prevalence of cerebral palsy.
- Enhanced education and training for healthcare professionals.
- Possible mitigation of the condition's prevalence.
Potential Disadvantages
- The bill's financial impact is relatively small given the scope of the problem.
- The research program's effectiveness depends on the Secretary's implementation.
- There is no guarantee of breakthroughs in treatment or prevention.
- The bill does not address the immediate needs of individuals with cerebral palsy.
- The program's focus may shift based on the Director of the CDC's discretion.
Constitutional Alignment
The bill aligns with the Constitution's mandate to "promote the general Welfare" (Preamble). Congress has the power to legislate on matters related to public health under the Commerce Clause (Article I, Section 8), as health and well-being affect interstate commerce. The bill's allocation of funds is subject to congressional appropriations, a power explicitly granted in Article I, Section 9.
Impact Assessment: Things You Care About ⓘ
This action has been evaluated across 19 key areas that matter to you. Scores range from 1 (highly disadvantageous) to 5 (highly beneficial).